Accéder au contenu
Merck

Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis.

Cell host & microbe (2020-04-17)
Irina Leonardi, Sudarshan Paramsothy, Itai Doron, Alexa Semon, Nadeem O Kaakoush, Jose C Clemente, Jeremiah J Faith, Thomas J Borody, Hazel M Mitchell, Jean-Frederic Colombel, Michael A Kamm, Iliyan D Iliev
RÉSUMÉ

Fecal microbiota transplantation (FMT) targeting gut microbiota has recently been successfully applied to ulcerative colitis. However, only a subset of patients responds to FMT, and there is a pressing need for biomarkers of responsiveness. Fungi (the mycobiota) represent a highly immunologically reactive component of the gut microbiota. We analyzed samples from a large randomized controlled trial of FMT for ulcerative colitis (UC). High Candida abundance pre-FMT was associated with a clinical response, whereas decreased Candida abundance post-FMT was indicative of ameliorated disease severity. High pre-FMT Candida was associated with increased bacterial diversity post-FMT, and the presence of genera was linked to FMT responsiveness. Although we detected elevated anti-Candida antibodies in placebo recipients, this increase was abrogated in FMT recipients. Our data suggest that FMT might reduce Candida to contain pro-inflammatory immunity during intestinal disease and highlight the utility of mycobiota-focused approaches to identify FMT responders prior to therapy initiation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Lyticase from Arthrobacter luteus, lyophilized powder, ≥2,000 units/mg protein, Protein ≥20 % by biuret